Purchase this article with an account.
N.T. Choplin, M.S. Dirks, M. Tepedino, A. Batoosingh, P. Bernstein, S.M. Whitcup, Bimatoprost/Latanoprost Study Group; Comparison of Clinically Relevant Response Rates to Bimatoprost and Latanoprost in Patients with Ocular Hypertension or Glaucoma . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2214.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: The American Academy of Ophthalmology's Preferred Practice Patterns for open angle glaucoma (2000) suggest that an initial target pressure for newly diagnosed glaucoma patients be at least 20% below baseline intraocular pressure (IOP). This study was conducted to compare the efficacy and safety of bimatoprost 0.03% with latanoprost 0.005% in patients with ocular hypertension (OHT) or glaucoma. This analysis was done to compare the percentage of patients in each treatment group that achieved at least a 20% decrease from baseline in IOP after receiving bimatoprost 0.03% or latanoprost 0.005%. Methods: This was a multicenter, investigator-masked, 6-month randomized clinical trial. After washout of currently used glaucoma medications, patients were randomly assigned to once daily bimatoprost 0.03% (n = 133) or latanoprost 0.005% (n = 136) administered in the evening. IOP was measured at week 1 and months 1, 3, and 6 at 8AM, 12PM and 4PM. Percentages of patients achieving at least 15% and 20% IOP reductions from baseline at all timepoints for each visit were calculated for each group and the percentages compared using Fisher's exact test. Results: The percentages of patients who achieved ≥ 20% IOP decrease from baseline at all measurements on a given visit were 68.4% in the bimatoprost group and 41.2% in the latanoprost group (P<.001) at week 1, 66.9% in the bimatoprost group and 47.1% in the latanoprost group (P = .001) at month 1, 60.2% in the bimatoprost group and 43.4% in the latanoprost group (P = .007) at month 3, and 57.9% in the bimatoprost group and 36.0% in the latanoprost group (P<.001) at month 6. At each visit, a greater percentage of bimatoprost patients than latanoprost patients also achieved at least a 15% IOP decrease from baseline at all measurements (P<.001). Conclusions: Patients on bimatoprost were significantly more likely than patients on latanoprost to achieve clinically relevant decreases from baseline IOP throughout the day.
This PDF is available to Subscribers Only